Quantitative Transmission Imaging Compared With MRI as Supplemental Screening for High Lifetime Risk of Breast Cancer

Completed · Not applicable

Conditions studied: Breast Carcinoma

In brief

This clinical trial compares the use of quantitative transmission imaging (QTI) to standard of care MRI as a supplemental screening tool for patients with a high lifetime risk of breast cancer. QTI is a single 3D ultrasound test intended to be used as an initial evaluation method for asymptomatic women identified with above-average risk for developing breast cancer. Using QTI may be an effective supplemental screening tool, compared to MRI for patients with a high lifetime risk of breast cancer.

Key facts

Study ID

NCT07216274

Run by

Mayo Clinic

People needed

26

Starts

2025-07-31

Expected to finish

2025-10-20

Last updated by the study team

2026-05-27

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Women 18+ years of age
• High lifetime risk of breast cancer as determined by a risk assessment tool such a Tyrer-Cuzick model
• Clinical ordered screening MRI.
• MRI and QTI performed within 30 days of each other
• Breasts that will fit in the quantitate transmission (QT) Ultrasound Breast Scanner (e.g. bra cup size less than DDD)

You may not qualify if…

• Pregnant patients
• Lactating patients
• Patients with open wounds or discharge
• Patients < 18 years of age
• Patients who are > 350 lbs
• Patients who are unable to lay prone for >15 minutes

Where it is running

• Mayo Clinic in Rochester — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.